EGFR靶向抑制剂,是目前NSCLC靶向治疗的研究热点之一。临床研究表明,患者对EGFR靶向抑制剂的疗效存在明显的差异。本文就EGFR酪氨酸激酶域基因突变与NSCLC靶向治疗的相关性进行了回顾,探讨预示其疗效的标志物,有助于EGFR抑制剂在NSCLC治疗中的最优化使用。 EGFR targeting inhibitor, is currently one of the hot topics in the targeted therapy of NSCLC. Clinical studies have shown that patients have significant differences in the efficacy of EGFR-targeted inhibitors. In this review, we reviewed the relationship between mutations in EGFR tyrosine kinase domain and targeted therapy in NSCLC, and explored the prognostic indicators of EGFR tyrosine kinase domain, which may be helpful for the optimal use of EGFR inhibitors in the treatment of NSCLC.